These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7056276)

  • 21. Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors.
    Sjöholm I; Kober A; Odar-Cederlöf I; Borgåa O
    Biochem Pharmacol; 1976 May; 25(10):1205-13. PubMed ID: 938543
    [No Abstract]   [Full Text] [Related]  

  • 22. Alterations of phenytoin protein binding with in vivo haemodialysis in dialysis encephalopathy.
    Steele WH; Lawrence JR; Elliott HL; Whiting B
    Eur J Clin Pharmacol; 1979 Feb; 15(1):69-71. PubMed ID: 421730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alteration of plasma albumin in relation to decreased drug binding in uremia.
    Boobis SW
    Clin Pharmacol Ther; 1977 Aug; 22(2):147-53. PubMed ID: 407044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid.
    Barré J; Chamouard JM; Houin G; Tillement JP
    Clin Chem; 1985 Jan; 31(1):60-4. PubMed ID: 3917383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.
    Oellerich M; Müller-Vahl H
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():61-70. PubMed ID: 6705428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A radioimmunoassay to measure piretanide in human serum and urine.
    Heptner W; Baudner S; Dagrosa EE; Hellstern C; Irmisch R; Strecker H; Wissmann H
    J Immunoassay; 1984; 5(1-2):13-27. PubMed ID: 6715550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extraction of uraemic toxins with activated carbon restores the functional properties of albumin.
    Sarnatskaya VV; Lindup WE; Ivanov AI; Yushko LA; Tjia J; Maslenny VN; Gurina NM; Nikolaev VG
    Nephron Physiol; 2003; 95(1):p10-8. PubMed ID: 14520007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heat inhibition of in vitro lipolysis and 14C ibuprofen protein binding in plasma from heparinized uraemic subjects.
    Pearce GA; Brown KF
    Life Sci; 1983 Oct; 33(15):1457-66. PubMed ID: 6621250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative evaluation of ototoxic side effects of furosemide, piretanide, bumetanide, azosemide and ozolinone in the cat--a new approach to the problem of ototoxicity.
    Göttl KH; Roesch A; Klinke R
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):275-82. PubMed ID: 4088324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of piretanide, a potassium stable diuretic, on serum electrolytes in patients with congestive heart failure.
    Verho M; Bückert C; Freude J; Jaeger S; Pahnke K
    Pharmatherapeutica; 1985; 4(5):288-95. PubMed ID: 3906674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced in vitro binding of tryptophan by plasma in uremia.
    de Torrente A; Glazer GB; Gulyassy P
    Kidney Int; 1974 Oct; 6(4):222-9. PubMed ID: 4427418
    [No Abstract]   [Full Text] [Related]  

  • 33. The alteration of plasma proteins in uremia as reflected in the ability to bind diphenylhydantoin.
    Shoeman DW; Benjamin DM; Azarnoff DL
    Ann N Y Acad Sci; 1973 Nov; 226():127-30. PubMed ID: 4520391
    [No Abstract]   [Full Text] [Related]  

  • 34. Piretanide, a potassium stable diuretic, in the treatment of essential hypertension.
    Verho M; Rangoonwala B; Dols W; Fratzer U; Kaczynski J; Mühlhäusler W
    Eur J Clin Pharmacol; 1984; 27(4):407-14. PubMed ID: 6394349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia.
    Takamura N; Maruyama T; Otagiri M
    Clin Chem; 1997 Dec; 43(12):2274-80. PubMed ID: 9439444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased drug binding in uraemia: effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin.
    Bowmer CJ; Lindup WE
    Biochem Pharmacol; 1982 Feb; 31(3):319-23. PubMed ID: 6803808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Removal of protein-bound uraemic toxins by haemodialysis.
    Niwa T
    Blood Purif; 2013; 35 Suppl 2():20-5. PubMed ID: 23676831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Underestimation of serum albumin by the bromcresol purple method and a major endogenous ligand in uremia.
    Mabuchi H; Nakahashi H
    Clin Chim Acta; 1987 Jul; 167(1):89-96. PubMed ID: 3665090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective effect of loop diuretics, piretanide and frusemide, against sodium metabisulphite-induced bronchoconstriction in asthma.
    Yeo CT; O'Connor BJ; Chen-Worsdell M; Barnes PJ; Chung KF
    Eur Respir J; 1992 Nov; 5(10):1184-8. PubMed ID: 1486963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of piretanide tablets, penbutolol tablets and the fixed combination of both drugs in healthy male subjects after a single oral dose.
    Müller F; Meyer B; Grigoleit HG
    Int J Clin Pharmacol Res; 1987; 7(6):469-75. PubMed ID: 3440637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.